Published in Blood Weekly, March 30th, 2000
"Identification of new therapeutic targets for the management of septic shock remains imperative as all investigational therapies, including anti-tumor necrosis factor (TNF) and anti-interleukin (IL)-1 agents, have uniformly failed to lower the mortality of critically ill patients with severe sepsis," reported T. Calandra and colleagues in Switzerland ("Protection from septic shock by neutralization of macrophage migration inhibitory factor," Nature Medicine, February 2000;6(2):164-170).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.